Pharmacy

Bausch Health: Spin-off of eye health business

This action will result in 2 separate companies,

Glaucoma 360: Drug delivery contact lens technology

ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface disease, during the 2020 Glaucoma 360 meeting in San Francisco, California.

Glaucoma 360: Pharmaceuticals in the glaucoma industry

ICYMI: Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline at Allergan, discusses glaucoma from a therapeutics/diagnostics and big data sets standpoint during the 2020 Glaucoma 360 meeting.

Bepostastine solution provides comfort, safety

February 15, 2010

Bepostastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) is safe and well-tolerated in healthy children as young as 3 years of age, according to results from a multicenter, prospective, double-masked, randomized, placebo-controlled trial.

Concomitant use of tear products with cyclosporine assessed

February 15, 2010

Blink Tears Lubricating Eye Drops improved dry eye symptoms significantly better than Systane Lubricant Eye Drops when the artificial tears were paired with topical cyclosporine ophthalmic emulsion.

Topical corticosteroid valuable option in allergic conjunctivitis care

February 15, 2010

For patients who are suffering with moderate to severe signs and symptoms of seasonal or perennial allergic conjunctivitis, loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb) is a safe and well-tolerated therapeutic option that can provide rapid clinical improvement, according to new research.

Efficacy of artificial tears tested under arid conditions

February 15, 2010

An efficacy evaluation comparing two marketed artificial tears showed that a polyethylene-based product (Systane Ultra, Alcon Laboratories) resulted in statisically greater reductions in corneal and conjunctival staining than a glycerin/carboxymethylcellulose-based tear (Refresh Optive, Allergan).

Allergy: Choosing the right anti-allergic drop

February 15, 2010

The overall anti-allergic eye drop market consists of about 25 products developed and approved in the United States (with some marketed abroad) to address the needs of the seasonal allergic conjunctivitis patient population.

Ophthalmic insert offers additional relief as adjunct dry eye therapy

February 15, 2010

The use of a hydroxypropyl cellulose ophthalmic insert (Lacrisert, Aton Pharma) has been proven to offer much relief to patients suffering from dry eye syndrome.

Iontophoresis: A new focus

February 15, 2010

A phase II study with a novel non-invasive iontopohoretic drug delivery system (EyeGate II Delivery System, EyeGate Pharma) shows that the device appears to optimize the delivery of a proprietary dexamethasone-derived corticosteroid solution (EGP-437) and improve significantly the signs and symptoms of dry eye, which may raise the bar in therapies for dry eye syndrome.